WHAT IS CLAIMED IS:

1. Use of stem cells in the manufacture of a medicament to deliver stem cells to a target tissue or organ while inhibiting binding of said stem cells to spleen, Peyer's patches, lymph nodes or other secondary lymphoid tissue,

wherein, the stem cells is to be administered in conjunction with a therapeutic agent that inhibits binding of the stem cells to said lymphoid tissue but does not inhibit binding of said stem cells to the target organ or tissue~~,~~.

~~2. The use of claim 1~~ wherein the therapeutic agent inhibits binding of the stem cells to germinal centers within the lymphoid tissue~~,~~ and

wherein the stem cells are to be administered to treat a disease selected from the group consisting of: osteopetrosis, limbal stem cell deficiency, acute myocardial infarction, coronary artery disease, peripheral vascular disease, heart failure, type I diabetes mellitus, type 2 diabetes mellitus, stroke, spinal cord injury, multiple sclerosis, systemic sclerosis, lupus erythematosus, chronic wound healing, burns, fracture healing, cartilage repair, osteoarthritis, renal failure, Parkinson's Disease, myelomas, diabetic foot, liver and biliary cirrhosis, dilated cardiomyopathy, retinitis pigmentosa, Crohn's Disease, diabetic neuropathy, mastocytosis, epilepsy, myasthenia gravis, autoimmune diseases, granulomatous disease, osteonecrosis, liver failure, PMD disease, lypodystrophy, demyelinating diseases, cartilage defects, retinal disease, lupus nephritis, Alzheimer's Disease, traumatic brain injury, myositis, hyperglycemia, macular degeneration, ulcerative colitis, and muscle degeneration,

~~3~~2. The use of claim ~~1~~2 wherein the germinal centers are present in a lymph tissue selected from the group consisting of spleen, Peyer's patches and lymph node tissue.

~~4~~3. The use of claim ~~2~~1 wherein the germinal center is active.

~~5~~4. The use of claim 1, wherein the therapeutic agent is selected from the group consisting of:

~~agents that interfere with the synthesis of purines, the anti-metabolites, radiation to the spleen, chemotherapeutic agents, immunosuppressants,~~ glucocorticoids, dexamethasone~~anti-beta amyloid agents, anti-rhesus factor~~, anti-TNF agents, anti-CD26 inhibitors, and DPPIV inhibitors ~~anti-eotaxins, anti-T cell receptor (TCR) agents, anti-interferons agents, anti-interferon alpha agents, anti-interferon beta agents, anti-interferon gamma agents, anti-TGF agents, anti-TGFalpha agents, anti-TGF beta agents, anti-Integrins agents, anti-alpha 4 agents, anti-Interleukin agents, anti-Interleukin 1 agents, anti-interleukin 2 agents, anti-Interleukin 4 agents, anti-interleukin 5 agents, anti-interleukin 6 agents, anti-Interleukin 12 agents, anti-Interleukin 13 agents, anti-Interleukin 23 agents, anti-~~

~~IgE agents, anti-Vascular Adhesion Protein (VAP) agents, anti-B7 agents, anti-Vascular Endothelial Growth Factor (VEGF) agents, anti-BAFF (BLyS) agents, anti-CTLA4 agents, anti-complement agents, anti-CD2 agents, anti-CD3 agents, anti-CD4 agents, anti-CD5 agents, anti-CD20 agents, anti-CD23 agents, anti-CD25a agents, anti-CD40 agents, anti-CD154 (CD40L) agents, anti-CD62L agents, anti-CD80 agents, anti-CD147 agents, anti-LFA1 agents, anti-(CD11a) agents, anti-CD18 agents, inhibitors of purine synthesis, inhibitors of pyrimidine synthesis, anti-proliferative agents, anti-metabolite agents, anti-folate agents, and anti-mTOR agents~~.

~~6~~5. The use of claim 1 wherein the therapeutic agents are selected from the group consisting of: ~~azathioprine, mycophenolic acid, leflunomide, teriflunomide, methotrexate, tacrolimus,~~ ciclosporin, ~~pimecrolimus, abetimus, gusperimus, thalidomide, lenalidomide, anakinra, sirolimus, deforolimus, everolimus, temsirolimus, zotarolimus, biolimus A9, eculizumab,~~ infliximab, ~~adalimumab, certolizumab pegol, afelimomab, golimumab, mepolizumab, omalizumab, nerelimomab, faralimomab, elsilimomab, lebrikizumab, ustekinumab, muromonab-CD3, otelixizumab, teplizumab, visilizumab, clenoliximab, keliximab, zanolimumab, efalizumab, erlizumab, afutuzumab, ocrelizumab, pascolizumab, lumiliximab, teneliximab, toralizumab, aselizumab, galiximab, gavilimomab, ruplizumab, belimumab, ipilimumab, tremelimumab, bertilimumab, lerdelimumab, metelimumab, natalizumab, tocilizumab, odulimomab, basiliximab, daclizumab, inolimomab, zolimomab aritox, atorolimumab, cedelizumab, dorlixizumab, fontolizumab, gantenerumab, gomiliximab, maslimomab, morolimumab, pexelizumab, reslizumab, rovelizumab, siplizumab, talizumab, telimomab aritox, vapaliximab, vepalimomab, abatacept, belatacept,~~ etanercept, sitagliptin, vildagliptin, saxagliptin, linagliptin, dutogliptin, denagliptin, gemigliptin, alogliptin, RO4876904, GRC 8200, KRP-104, ASP1941, Berberine, IP10.C8, Diprotin A. ~~pegsunercept, aflibercept, alefacept, rilonacept, lymphotoxin alpha and beta inhibitors, dacetuzumab SGN-40, HCD-12.~~

~~7~~6. The use of claim 1, wherein the binding of stem cells to the lymphoid tissue is inhibited by the administration of a therapeutic agent that down-regulates or blocks a CD45 antigen.

~~8~~7. The use of claim 1 wherein the therapeutic agent is radiation.

~~9~~8. The use of claim 1 wherein the stem cells are either exogenous or endogenous stem cells.

~~10. The use of claim 1 wherein the therapeutic agent is a chemotherapeutic agent.~~

~~11. The use of claim 1 wherein the stem cells are to be administered to treat a disease selected from the group consisting of: hematological malignancies, leukemias, lymphomas, cancers, osteopetrosis, aplastic anemia and cytopenias, sickle cell disease and thalassemia, limbal stem cell deficiency, breast cancer, acute myocardial infarction, coronary artery disease, peripheral vascular disease, heart failure, type I diabetes mellitus, type 2 diabetes mellitus, stroke, spinal cord injury, neuroblastoma, multiple sclerosis, systemic sclerosis, lupus erythematosus, chronic wound healing, burns, fracture healing, cartilage repair, CNS tumors, osteoarthritis, renal failure, Parkinson's Disease, myelomas, diabetic foot, liver and biliary cirrhosis, dilated cardiomyopathy, anemia, retinitis pigmentosa, Crohn's Disease, diabetic neuropathy, mastocytosis, ovarian cancer, epilepsy, myasthenia gravis, autoimmune diseases, granulomatous disease, osteonecrosis, liver failure, PMD disease, lypodystrophy, demyelinating diseases, cartilage defects, retinal disease, lupus nephritis, Alzheimer's Disease, traumatic brain injury, sarcoma, myositis, hyperglycemia, macular degeneration, ulcerative colitis, and muscle degeneration.~~

~~12~~9. Use of a therapeutic agent ~~–~~that inhibits the formation of the germinal cells or promotes destruction or ablation of the germinal cells in the manufacture of a medicament for inhibiting binding of stem cells to lymph tissues in an individual; wherein inhibiting binding of stem cells to lymph tissues comprises inhibiting the formation of germinal centers present in lymph tissues or destroying or ablating germinal centers in lymph tissue.

~~13~~10. The use of claim ~~12~~9; wherein the therapeutic agent is selected from the group consisting of agents that interfere with the synthesis of purines, anti-metabolites, radiation, immunosuppressants, glucocorticoids, anti-beta amyloid agents, anti-rhesus factor, anti-TNF agents, anti-eotaxins, anti-T cell receptor (TCR) agents, anti-interferons agents, anti-interferon alpha agents, anti-interferon beta agents, anti-interferon gamma agents, anti-TGF agents, anti-TGFalpha agents, anti-TGF beta agents, anti-Integrins agents, anti-alpha 4 agents, anti-Interleukin agents, anti-Interleukin 1 agents, anti-interleukin 2 agents, anti-Interleukin 4 agents, anti-interleukin 5 agents, anti-interleukin 6 agents, anti-Interleukin 12 agents, anti-Interleukin 13 agents, anti-Interleukin 23 agents, anti-IgE agents, anti-Vascular Adhesion Protein (VAP) agents, anti-B7 agents, anti-Vascular Endothelial Growth Factor (VEGF) agents, anti-BAFF (BLyS) agents, anti-CTLA4 agents, anti-complement agents, anti-CD2 agents, anti-CD3 agents, anti-CD4 agents, anti-CD5 agents, anti-CD20 agents, anti-CD23 agents, anti-CD25a agents, anti-CD40 agents, anti-CD154 (CD40L) agents, anti-CD62L agents, anti-CD80 agents, anti-CD147 agents, anti-LFA1 agents, anti-(CD11a) agents, anti-CD18 agents, inhibitors of purine synthesis, inhibitors of pyrimidine synthesis, anti-proliferative agents, anti-metabolite agents, anti-folate agents, and anti-mTOR agents.

~~14~~11. The use of claim ~~12~~9 wherein the therapeutic agent is a chemotherapeutic agent.

~~15~~12. Use of one or more agents that stimulates regeneration of the germinal centers in the manufacture of a medicament for regenerating germinal centers in lymphatic tissue, wherein said germinal centers have been damaged by a chemical agent, a biologic agent or by radiation.

13. The use of Claim 1, wherein the stem cells are selected from the group consisting of: mesenchymal, mesodermal, adipose, stromal vascular, induced pluripotent, embryonic, olfactory, epidermal, neural, limbal, skin, cardiac, skeletal, myoblasts, oval, liver, epithelial, intestinal, pancreatic, corneal, and keratinocyte.

14. The use of any one of claims 1-8 and 13, wherein the stem cells are not derived from a human embryo greater than 14 days old.